CN113336827A - 一种低分子量抗菌肽yhx-2及其组合物和应用 - Google Patents
一种低分子量抗菌肽yhx-2及其组合物和应用 Download PDFInfo
- Publication number
- CN113336827A CN113336827A CN202110737063.5A CN202110737063A CN113336827A CN 113336827 A CN113336827 A CN 113336827A CN 202110737063 A CN202110737063 A CN 202110737063A CN 113336827 A CN113336827 A CN 113336827A
- Authority
- CN
- China
- Prior art keywords
- yhx
- peptide
- antibacterial
- antibacterial peptide
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 31
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 31
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 241000186779 Listeria monocytogenes Species 0.000 claims description 9
- 241000607142 Salmonella Species 0.000 claims description 9
- 241000191967 Staphylococcus aureus Species 0.000 claims description 9
- 241000194019 Streptococcus mutans Species 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- -1 body wash Substances 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 14
- 230000002949 hemolytic effect Effects 0.000 abstract description 7
- 241000192125 Firmicutes Species 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 244000052616 bacterial pathogen Species 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000013882 gravy Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101100379209 Arabidopsis thaliana APD3 gene Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3526—Organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Environmental Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pest Control & Pesticides (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Agronomy & Crop Science (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Abstract
本发明属于生物技术领域，具体涉及一种低分子量抗菌肽YHX‑2及其组合物和应用，所述抗菌肽YHX‑2的氨基酸序列如SEQ ID No.1所示。该抗菌肽具有人工合成简单、抗菌作用显著和溶血活性低的特点；其具有广谱的抗菌活性，能够抑制革兰氏阳性菌和革兰氏阴性菌，且均具有较高的抗菌活性；其合成序列短，分子量小，化学合成难度小，能够更加特异性地杀死生物体内的病原菌的同时很好的节约规模化生产成本，具有广泛的应用前景。
Description
技术领域
本发明属于生物技术领域，具体涉及一种低分子量抗菌肽YHX-2及其组合物和应用。
背景技术
自弗莱明发现青霉素以来，抗生素就在人类与病原体的斗争中发挥着不可替代的作用，成为人类治疗感染疾病最常用的一类药物。但是由于抗生素的长期大量使用和滥用，导致近年来临床和畜牧业中的耐药菌株不断增多，也导致了多重耐药菌的出现。目前临床上常见的多重耐药菌有：耐甲氧西林金黄色葡萄球菌(MRSA)、多重耐药铜绿假单胞菌(MDR-PA)、多重耐药鲍曼不动杆菌(MDR-AB)以及耐万古霉素肠球菌(VRE)等。当前，病原菌的耐药性问题已经成为亟待解决的全球性公共卫生问题，而开发新型抗菌药物是解决此问题的一个重要途径。
抗菌肽(antimicrobial peptides，AMPs)是一类小分子多肽，广泛分布于动植物体内，是天然免疫系统的重要组成部分，具有包括抗细菌、抗真菌、抗病毒、杀灭寄生虫、抑制肿瘤以及调节免疫系统等多种生物活性。同时，抗菌肽因其独特的膜破坏机制和胞内杀菌机制而不易产生耐药性，从而具有广泛的应用前景。
虽然抗菌肽在治疗细菌感染方面展现出巨大的潜力，然而目前大部分抗菌肽还存在生产成本高、生物活性较低以及易引发溶血等问题。因此，通过理性设计开发出结构简单、生物活性高同时无明显毒副作用的抗菌肽是目前的研究热点之一。
发明内容
本发明的目的在于解决现有技术中存在的上述问题，提出了一种低分子量抗菌肽YHX-2及其组合物和应用，该新型抗菌肽对革兰氏阳性菌(单核细胞增生李斯特氏菌、金黄色葡萄球菌、变异链球菌)、革兰氏阴性菌(大肠杆菌、沙门氏菌)都有较好的抗菌活性，并且具有溶血活性低的特点，应用前景广泛。
本发明的技术方案是：
一种低分子量抗菌肽YHX-2，所述抗菌肽YHX-2的氨基酸序列如SEQ ID No.1所示，具体为Leu-Lys-Leu-Leu-Ser-Lys-Leu-Leu-Gly-Lys-Leu-Leu-Lys-NH2。
进一步的，所述抗菌肽YHX-2包含13个氨基酸残基，其分子量为1466.96Da，净电荷数为+4。
所述的抗菌肽YHX-2在制备生物抗菌剂中的应用。
进一步，所述生物抗菌剂以抗菌肽YHX-2为主要成分，所述生物抗菌剂用于抑制革兰氏阳性菌和革兰氏阴性菌，包括单核细胞增生李斯特氏菌、变异链球菌、沙门氏菌、大肠杆菌和金黄色葡萄球菌。
进一步的，所述抗菌肽YHX-2对单核细胞增生李斯特氏菌的最小抑菌浓度为4μg/mL；对变异链球菌的最小抑菌浓度为16μg/mL；对沙门氏菌的最小抑菌浓度为8μg/mL；对大肠杆菌的最小抑菌浓度为16μg/mL；对金黄色葡萄球菌的最小抑菌浓度为256μg/mL。
所述的抗菌肽YHX-2在制备防腐剂或者动物饲料中的应用，所述动物饲料包括所述抗菌肽YHX-2或其任意比例的混合物；所述防腐剂包括所述抗菌肽YHX-2或其任意比例的混合物。
进一步的，所述防腐剂为用于食品或化妆品的防腐剂。
一种组合物，所述组合物为含有所述抗菌肽YHX-2或其任意比例的混合物。
进一步的，所述组合物为洗手液、香皂、沐浴液、洗发剂、牙膏、洗衣液或洗衣粉等。
本发明的有益效果：
本发明所提供的抗菌肽YHX-2具有人工合成简单、抗菌作用显著和溶血活性低的特点；其具有广谱的抗菌活性，能够抑制革兰氏阳性菌，如单核细胞增生李斯特氏菌、金黄色葡萄球菌、变异链球菌等，和革兰氏阴性菌，如大肠杆菌、沙门氏菌等；且均具有较高的抗菌活性。
本发明的抗菌肽溶血活性较低，合成序列短，分子量小，化学合成难度小，能够更加特异性地杀死生物体内的病原菌，同时很好的节约规模化生产成本，具有广泛的应用前景。
附图说明
图1为本发明提供的抗菌肽YHX-2的螺旋轮结构示意图；
图2为本发明提供的抗菌肽YHX-2的二级结构预测示意图；
图3为本发明提供的抗菌肽YHX-2在333μg/mL浓度条件下对单核细胞增生李斯特氏菌的抑菌效果示意图；
图4为本发明提供的抗菌肽YHX-2在333μg/mL浓度条件下对大肠杆菌的抑菌效果示意图；
图5为本发明提供的抗菌肽YHX-2在333μg/mL浓度条件下对变异链球菌的抑菌效果示意图；
图6为本发明提供的抗菌肽YHX-2在333μg/mL浓度条件下对沙门氏菌的抑菌效果示意图。
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
为了进一步理解本发明，将结合附图和实施例对本发明作进一步的说明。
实施例1抗菌肽的设计
在抗菌肽从头设计及对构效关系理解的基础上，对从APD3数据库中筛选得到的针对革兰氏阳性菌和革兰氏阴性菌有抑菌作用的843条抗菌肽序列进行序列参数分析，包括序列长度、带电荷数、疏水氨基酸比例和氨基酸组成等参数的分析，然后按照优势参数选取原则并结合理性设计思路，确定了新抗菌肽的各项序列参数，具体如下表1所示：
表1从头设计抗菌肽的序列参数
| 序列长度 | 带电荷数 | 疏水氨基酸个数 | 氨基酸组成 |
| 13 | +4 | 7 | Gly、Lys、Ser、Leu |
综合考虑溶血活性以及合成成本等因素，选择在抗菌肽数据库中出现频数第二位的13作为抗菌肽YHX-2的序列长度。选取带正电氨基酸Lys和极性不带电荷氨基酸Ser组成抗菌肽的极性面，选取疏水性氨基酸Leu形成疏水面，以此来形成抗菌肽YHX-2的两亲性结构；带电荷数确定为+4，保证抗菌肽对细菌细胞膜的亲和力。
采用生物信息学预测及分析工具进行抗菌肽一级结构的辅助设计，对不同氨基酸排列顺序的肽序列分子量、平均疏水值、平均疏水力矩、不稳定性指数、脂肪族指数、半衰期、螺旋轮图、成为AMPs的可能性以及二级结构进行预测，筛选得到最优的肽序列。
所用生物信息学工具如下：
物化性质分析网站：Expasy ProtParam(https://web.expasy.org/protparam/)；
螺旋轮图及疏水性分析网站：Heliquest(https://heliquest.ipmc.cnrs.fr/)；
AMPs可能性预测网站：CAMPR3(http://www.camp.bicnirrh.res.in/)；
二级结构预测网站：
Pep-fold(https://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD3/)；
Zhang Lab(https://zhanglab.ccmb.med.umich.edu/)
通过上述工具得到的最优抗菌肽序列及物化性质如表2所示，通过GRAVY(总平均疏水值)和疏水力矩可以看出肽序列具有较高的疏水性和疏水力矩，因而具有很好的两亲性，在对细菌细胞膜具有较好亲和力的同时有利于深入细胞膜的磷脂双分子层，进而破坏细胞膜的完整性。脂肪族指数(Aliphatic index)和不稳定指数(Instability index)均被认为与肽的稳定性相关，其中不稳定性指数低于40则表明了序列较好的稳定性，脂肪族指数代表了肽序列中脂肪族氨基酸所占的相对体积，与热稳定性相关，通过预测结果可知抗菌肽YHX-2具有较好的预测稳定性。
表2抗菌肽YHX-2的序列及物化性质
| 序列 | GRAVY | 脂肪族指数 | 不稳定指数 | 等电点 | 疏水力矩 |
| LKLLSKLLGKLLK | 0.754 | 210 | -29.95 | 10.48 | 0.749 |
图1为抗菌肽YHX-2的螺旋轮结构图，有4个Lys组成的亲水面位于螺旋的一侧，另一侧则由7个Leu组成了肽的疏水面，说明肽具有良好的两亲性。使用CAMPR3基于三种不同算法(SVM、Random Forest、ANN)对抗菌肽的成肽可能性进行预测，肽序列YHX-2的AMPProbability均在0.97以上。基于Pep-fold和Zhang Lab对肽序列YHX-2的二级结构预测结果如图2所示，表明抗菌肽YHX-2的呈现出明显的α-螺旋结构。
实施例2抑菌活性检测
抗菌肽由强耀生物科技(上海)有限公司合成，抗菌肽C末端进行了酰胺化修饰，纯度在95％以上。
将金黄色葡萄球菌、大肠杆菌和沙门氏菌分别划线接种于LB固体培养基，将单核细胞增生李斯特氏菌和变异链球菌划线接种于BHI固体培养基，置于37℃恒温培养箱培养18h，挑取各个菌株的单菌落置于各自对应的液体培养基中，37℃恒温振荡培养12h。测量菌液的OD600值，并将其稀释至1×106CFU/mL。
(1)抑菌圈实验
配制LB和BHI半固体培养基(琼脂质量分数0.6％)，每皿20mL加入7μL菌液振荡混匀后倒入摆放好牛津杯的培养皿中，待培养基冷却凝固后拔除牛津杯完成打孔，每孔中加入160μL抗菌肽溶液(配制使用1mg抗菌肽溶于3mL超纯水)。置于37℃恒温培养箱培养24h后测量抑菌圈直径，测试结果如图3-6所示。
(2)最小抑菌浓度(MIC)的测定
向96孔板中加入培养至对数生长期的各菌株菌液(单核细胞增生李斯特氏菌、变异链球菌、金黄色葡萄球菌、沙门氏菌、大肠杆菌)50μL，同时在各孔中加入各浓度梯度抗菌肽溶液(512μg/mL、256μg/mL、128μg/mL、64μg/mL、32μg/mL、16μg/mL、8μg/mL、4μg/mL)50μL，并分别做阳性对照和阴性对照组。在37℃恒温培养箱培养8h后测量各孔的OD600值，取菌株生长被完全抑制的最低浓度作为抗菌肽的最小抑菌浓度(MIC)，测试结果如表3所示。
表3抗菌肽YHX-2的抑菌活性分析结果
实施例3溶血活性检测
取新鲜健康兔血液1mL加于肝素抗凝管中，在1000xg转速下离心10min后取沉淀，用PBS缓冲液冲洗3次，将红细胞用10mLPBS重悬。用PBS缓冲液将抗菌肽YHX-2的浓度调整至4～512μg/mL，以每孔50μL的剂量加入加入96孔板中，并加入等体积(50μL)的红细胞悬液混匀。以PBS缓冲液作为阴性对照，以0.1％Tritonx-100作为阳性对照，在37℃恒温培养1h后取出，1000xg离心10min，取出上清液用酶标仪在570nm处测OD值，测试结果如表4所示。
溶血率计算公式为：溶血率＝(AT-AO)/(AC-AO)×100％；
式中，AT为实验组的吸光值，AC为阳性对照组的吸光值，AO为阴性对照组的吸光值。
表4抗菌肽YHX-2的溶血活性(测定3次取平均值)
| 抗菌肽浓度(μg/mL) | 32 | 64 | 128 | 256 | 512 |
| 溶血率(％) | 0 | 0 | 0 | 0.036 | 3.400 |
由表4可知，在最小抑菌浓度(MIC)条件下，抗菌肽YHX-2的溶血率均低于10％，且在低于128μg/mL浓度下，抗菌肽YHX-2无溶血活性，说明抗菌肽YHX-2有极好的安全性，在制作生物抗菌剂、防腐剂以及动物饲料等领域的应用前景较大，可进一步深入研究和开发利用。
上述说明仅为本发明的优选实施例，并非是对本发明的限制，尽管参照前述实施例对本发明进行了详细的说明，对于本领域技术人员来说，其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改型等，均应包含在本发明的保护范围之内。
序列表
<110> 中国海洋大学
<120> 一种低分子量抗菌肽YHX-2及其组合物和应用
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Leu Lys Leu Leu Ser Lys Leu Leu Gly Lys Leu Leu Lys
1 5 10
Claims (9)
1.一种低分子量抗菌肽YHX-2，其特征在于，所述抗菌肽YHX-2的氨基酸序列如SEQ IDNo.1所示。
2.根据权利要求1所述的抗菌肽YHX-2，其特征在于，所述抗菌肽YHX-2包含13个氨基酸残基，其分子量为1466.96Da，净电荷数为+4。
3.权利要求1所述的抗菌肽YHX-2在制备生物抗菌剂中的应用。
4.根据权利要求3所述的应用，其特征在于，所述生物抗菌剂以抗菌肽YHX-2为主要成分，所述生物抗菌剂用于抑制革兰氏阳性菌和革兰氏阴性菌，包括单核细胞增生李斯特氏菌、变异链球菌、沙门氏菌、大肠杆菌和金黄色葡萄球菌。
5.根据权利要求4所述的应用，其特征在于，所述抗菌肽YHX-2对单核细胞增生李斯特氏菌的最小抑菌浓度为4μg/mL；对变异链球菌的最小抑菌浓度为16μg/mL；对沙门氏菌的最小抑菌浓度为8μg/mL；对大肠杆菌的最小抑菌浓度为16μg/mL；对金黄色葡萄球菌的最小抑菌浓度为256μg/mL。
6.权利要求1所述的抗菌肽YHX-2在制备防腐剂或者动物饲料中的应用，其特征在于，所述动物饲料包括所述抗菌肽YHX-2或其任意比例的混合物；所述防腐剂包括所述抗菌肽YHX-2或其任意比例的混合物。
7.根据权利要求6所述的应用，其特征在于，所述防腐剂为用于食品或化妆品的防腐剂。
8.一种组合物，其特征在于，所述组合物为含有所述抗菌肽YHX-2或其任意比例的混合物。
9.根据权利要求8所述的组合物，其特征在于，所述组合物为洗手液、香皂、沐浴液、洗发剂、牙膏、洗衣液或洗衣粉。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110737063.5A CN113336827B (zh) | 2021-06-30 | 2021-06-30 | 一种低分子量抗菌肽yhx-2及其组合物和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110737063.5A CN113336827B (zh) | 2021-06-30 | 2021-06-30 | 一种低分子量抗菌肽yhx-2及其组合物和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113336827A true CN113336827A (zh) | 2021-09-03 |
| CN113336827B CN113336827B (zh) | 2022-04-05 |
Family
ID=77481888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110737063.5A Active CN113336827B (zh) | 2021-06-30 | 2021-06-30 | 一种低分子量抗菌肽yhx-2及其组合物和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113336827B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114516899A (zh) * | 2022-01-27 | 2022-05-20 | 中国海洋大学 | 抗菌肽yhx-5及其应用 |
| CN114516900A (zh) * | 2022-01-27 | 2022-05-20 | 中国海洋大学 | 抗菌肽yhx-4及其应用 |
| CN115724909A (zh) * | 2022-08-29 | 2023-03-03 | 扬州市扬大康源乳业有限公司 | 抗菌肽yhx-7及其应用 |
| CN116082461A (zh) * | 2022-10-14 | 2023-05-09 | 浙江大学 | 一种具有抗菌活性的小分子肽及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140309162A1 (en) * | 2011-12-30 | 2014-10-16 | Industry-Academic Cooperation Foundation, Chosun University | Novel antibacterial and fungicidal peptide in which lysine and tryptophan residues are repeated, and use thereof |
| CN112940082A (zh) * | 2021-04-23 | 2021-06-11 | 扬州市扬大康源乳业有限公司 | 一种抗菌肽及其应用 |
-
2021
- 2021-06-30 CN CN202110737063.5A patent/CN113336827B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140309162A1 (en) * | 2011-12-30 | 2014-10-16 | Industry-Academic Cooperation Foundation, Chosun University | Novel antibacterial and fungicidal peptide in which lysine and tryptophan residues are repeated, and use thereof |
| CN112940082A (zh) * | 2021-04-23 | 2021-06-11 | 扬州市扬大康源乳业有限公司 | 一种抗菌肽及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| 章检明等: "产抗菌肽乳酸菌筛选及抗菌肽的分离纯化与特性研究", 《食品安全质量检测学报》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114516899A (zh) * | 2022-01-27 | 2022-05-20 | 中国海洋大学 | 抗菌肽yhx-5及其应用 |
| CN114516900A (zh) * | 2022-01-27 | 2022-05-20 | 中国海洋大学 | 抗菌肽yhx-4及其应用 |
| CN114516899B (zh) * | 2022-01-27 | 2023-06-16 | 中国海洋大学 | 抗菌肽yhx-5及其应用 |
| CN114516900B (zh) * | 2022-01-27 | 2023-06-16 | 中国海洋大学 | 抗菌肽yhx-4及其应用 |
| CN115724909A (zh) * | 2022-08-29 | 2023-03-03 | 扬州市扬大康源乳业有限公司 | 抗菌肽yhx-7及其应用 |
| CN115724909B (zh) * | 2022-08-29 | 2023-11-28 | 扬州市扬大康源乳业有限公司 | 抗菌肽yhx-7及其应用 |
| CN116082461A (zh) * | 2022-10-14 | 2023-05-09 | 浙江大学 | 一种具有抗菌活性的小分子肽及其应用 |
| CN116082461B (zh) * | 2022-10-14 | 2023-11-14 | 浙江大学 | 一种具有抗菌活性的小分子肽及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113336827B (zh) | 2022-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113336827B (zh) | 一种低分子量抗菌肽yhx-2及其组合物和应用 | |
| CN113336828B (zh) | 抗菌肽yhx-3及其组合物和应用 | |
| CN112940082B (zh) | 一种抗菌肽及其应用 | |
| Zhang et al. | Potential of novel antimicrobial peptide P3 from bovine erythrocytes and its analogs to disrupt bacterial membranes in vitro and display activity against drug-resistant bacteria in a mouse model | |
| Yacoub et al. | Antimicrobial activities of chicken β-defensin (4 and 10) peptides against pathogenic bacteria and fungi | |
| CN107383175B (zh) | 一种抗菌肽vk-21及其应用 | |
| CN114516900B (zh) | 抗菌肽yhx-4及其应用 | |
| Hu et al. | Lipopolysaccharide neutralization by a novel peptide derived from phosvitin | |
| CN113121666B (zh) | 抗菌肽Scybaumancin105-127及其应用 | |
| CN106543271A (zh) | 抗耐药性感染多肽Cbf‑14‑2及其用途 | |
| de Souza et al. | Peptides as a therapeutic strategy against Klebsiella pneumoniae | |
| CN114516899B (zh) | 抗菌肽yhx-5及其应用 | |
| CN102382186B (zh) | 衍生自线性鸡β-防御素4(RL38)的抗菌肽GLI23及其制备方法 | |
| Kim et al. | Effects of the synthetic coprisin analog peptide, CopA3 in pathogenic microorganisms and mammalian cancer cells | |
| JP2005120050A (ja) | 新規抗菌性ペプチドとその利用 | |
| CN115724909B (zh) | 抗菌肽yhx-7及其应用 | |
| CN109627286A (zh) | 一种新型广谱抗菌肽samp1-a4及其制备方法 | |
| Kim et al. | Development of a novel short synthetic antibacterial peptide derived from the swallowtail butterfly Papilio xuthus larvae | |
| Lu et al. | Novel cathelicidin‐derived antimicrobial peptides from Equus asinus | |
| JP4154218B2 (ja) | 新規抗菌性ポリペプチドとその利用 | |
| KR101465098B1 (ko) | 융합 항균펩타이드 ｐａｊｅ 및 이를 합성하는 방법 | |
| CN112724198A (zh) | 一种抗耐甲氧西林金黄色葡萄球菌抗菌肽及其制备方法和应用 | |
| CN117903253A (zh) | 一种抗菌肽rv15及其应用 | |
| CN114773436B (zh) | 一种拟穴青蟹抗菌多肽SpRR20及其应用 | |
| Shah et al. | Synthetic antimicrobial peptide identified using artificial intelligence inhibit growth of antibiotic resistant Pseudomonas aeruginosa in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |